Perspective Therapeutics (CATX) Return on Capital Employed (2011 - 2026)

Perspective Therapeutics has disclosed Return on Capital Employed across 15 years of filings, most recently posting 39.04% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 39.04%, down 813.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 39.04% (down 813.0% YoY), and the FY2025 annual result was 41.24%, up 391.0% from the prior year.
• Return on Capital Employed came in at 39.04% for Q1 2026 at Perspective Therapeutics, up from 45.03% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 6.09% in Q1 2022 to a low of 46.24% in Q4 2023.
• The 5-year median for Return on Capital Employed is 25.45% (2024), against an average of 27.16%.
• Across the five-year window, Return on Capital Employed jumped 2012 bps in 2024 and sank 2610 bps in 2025, its largest moves.
• Perspective Therapeutics' Return on Capital Employed stood at 23.27% in 2022, then plunged by 99 bps to 46.24% in 2023, then soared by 44 bps to 26.12% in 2024, then plunged by 72 bps to 45.03% in 2025, then climbed by 13 bps to 39.04% in 2026.
• The last three Return on Capital Employed figures came in at 39.04% (Q1 2026), 45.03% (Q4 2025), and 42.07% (Q3 2025), per Business Quant data.